Cannabinoids as antitumoral agents: from bench to bedside

There is compelling evidence indicating that cancer is one of the pathologies that may obtain clinical benefit from cannabis-related compounds. First, it is well known that cannabinoids have palliative effects in cancer patients. In particular, they inhibit chemotherapy-induced nausea and vomiting, they inhibit cancer-associated pain and they stimulate appetite and attenuate wasting. But the therapeutic potential of cannabinoids in oncology might not be restricted to their aforementioned palliative actions.

Thus, numerous studies carried out dur¬ing the past few years have provided evidence showing that THC and other cannabinoids induce the death of cancer cells in culture and reduce tumor growth and progression in a wide range of animal models of cancer. The mechanisms of anti-tumor action include the induction of cancer cell death, an effect that is not produced in non-cancer cells, the inhibition of angiogenesis and the blockade of invasion and metastasis. At this point, combined efforts from basic researchers, clinicians and pharmaceutical companies should be made to transfer this knowledge from the labs to the clinics.

Your are cordially invited to the annual conference at Cannafest, the international trade fair of cannabis and medical herbs that will take place on November 11-13, 2016 at the Prague Exhibition Holesovice. The conference presentations will be simultaneously interpreted into English and Czech.

_____________________________________________

www.cannafest.com